JimmyRuizMD

Thoracic Cancer

Professor of Medicine, Hematology and Oncology Assistant Director for Clinical Research Wake Forest Comprehensive Cancer Center Section Chief, Hematology and Oncology Salisbury VAMC Deputy ACOS Medicine, VAMC Salisbury

Join to view full profile

Dr. Ruiz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ruiz's full profile

Already have an account?

Office
Medical Center Blvd
Winston-Salem, NC 27157
Phone+1 336-716-2255

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2004 - 2007
Southern Illinois University School of MedicineClass of 2004

Certifications & Licensure

NC State Medical License 2004 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine

Clinical Trials

Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates Start of enrollment: 2012 Jun 01
Completed
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy Start of enrollment: 2014 Feb 01
Terminated
Not Applicable
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Start of enrollment: 2021 Apr 14
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis.
Abhishek Tyagi, Shih-Ying Wu, Sambad Sharma, Kerui Wu, Dan Zhao
Oncogene. 2025-02-01
Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening.
Dan Zhao, Ravindra Deshpande, Kerui Wu, Abhishek Tyagi, Sambad Sharma
Neoplasia. 2025-02-01
Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study.
John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko
Immunotherapy. 2025-01-01

Press Mentions

Jimmy Ruiz, MD: Biomarkers in Thoracic CancerJanuary 30th, 2025
How Atrium Health Researchers Are Making Clinical Trials More Accessible to Underserved PopulationsJune 14th, 2022